Beam Therapeutics

Beam Therapeutics Inc.
TypePublic
ISINUS07373V1052
IndustryBiotechnology
Founded2017 (2017)
Founders
HeadquartersCambridge, Massachusetts, U.S.
Key people
  • John Evans (CEO)
  • Giuseppe Ciaramella (CSO)
Number of employees
341 (December 31, 2021)[1]
Websitebeamtx.com

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.[2][3]

History

Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[4] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.[5]

In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.[6][7]

In 2026 clinical trial results were published on Beam's investigational medicine, ristoglogene autogetemcel, a CRISPR-based gene therapy for treatment of sickle cell disease.[8]

See also

References

  1. ↑ "Beam Therapeutics Inc. FORM 10-K". U.S. Securities and Exchange Commission. Retrieved 14 December 2022.
  2. ↑ "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ. Archived from the original on 2021-08-07.
  3. ↑ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.
  4. ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2.
  5. ↑ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.
  6. ↑ "Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases". Pfizer.
  7. ↑ Alpert, Bill. "Pfizer and Beam Partner to Develop Treatments for 3 Genetic Diseases". www.barrons.com. Retrieved 2022-02-04.
  8. ↑ Gupta, Ashish (1 April 2026). "Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease". New England Journal of Medicine. doi:10.1056/NEJMoa2504835. Retrieved 12 Jun 2026.
  • Official website
  • Business data for Beam Therapeutics Inc.:
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.